Concept
Clinical Barriers
Future of Cancer Science | AACR Cancer Progress Report 2025 / Detecting Minimal Residual Disease and Recurrence
"Although liquid biopsy has shown promise in enhancing current methods of cancer detection and monitoring, challenges remain that limit its routine clinical use (see Sidebar 55). Researchers have highlighted key barriers to ctDNA adoption, some of which include a variable amount of detectable material and lack of standardized protocols (1091)Bartolomucci A, et al. (2025) NPJ Precis Oncol, 9: 84.. Overcoming these hurdles through continued research will be essential to fully unlock the potential of liquid biopsies to personalize cancer care and guided treatment."
Related Ideas
- MRD DetectionFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Kidney MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Early DiagnosisFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Dynamic CtdnaFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Immune ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Risk StratificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- KRAS ProfilingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- BiomarkersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Improving Detection and Diagnosis